Current views on anthracycline cardiotoxicity

CADEDDU DESSALVI, CHRISTIAN;MERCURO, GIUSEPPE
2016-01-01

Abstract

Anthracyclines are well established and effective anticancer agents used to treat a variety of adult and pediatric cancers. Unfortunately, these drugs are also among the commonest chemotherapeutic agents that have been recognized to cause cardiotoxicity. In the last years, several experimental and clinical investigations provided new information and perspectives on anthracycline-related cardiotoxicity. In particular, molecular mechanisms of cardiotoxicity have been better elucidated, early diagnosis has improved through the use of advanced noninvasive cardiac imaging techniques, and emerging data indicate a genetic predisposition to develop anthracycline-related cardiotoxicity. In this article, we review established and new knowledge about anthracycline cardiotoxicity, with special focus on recent advances in cardiotoxicity diagnosis and genetic profiling.
2016
Inglese
HEART FAILURE REVIEWS
21
5
621
634
14
WOS:000387227900014
2-s2.0-84969916318
27230651
https://link.springer.com/article/10.1007%2Fs10741-016-9564-5
Esperti anonimi
internazionale
scientifica
Anthracyclines; Cancer; Cardiotoxicity; Cardiology and Cardiovascular Medicine
no
Mele, Donato; Nardozza, Marianna; Spallarossa, Paolo; Frassoldati, Antonio; Tocchetti, Carlo G.; CADEDDU DESSALVI, Christian; Madonna, Rosalinda; Mala ...espandi
1.1 Articolo in rivista
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
10
reserved
Files in This Item:
File Size Format  
Mele HF Rew'16.pdf

Solo gestori archivio

Type: versione editoriale
Size 495.93 kB
Format Adobe PDF
& nbsp; View / Open   Request a copy
495.93 kB Adobe PDF & nbsp; View / Open   Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie